Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | LMNA | P02545 | 5/20 | 0.57 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.57 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.57 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.57 |
| ▸ | BCHE | P06276 | 1/20 | 0.57 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.57 |
| ▸ | ACHE | P22303 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | AKT1 | P31749 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.53 |
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11073619 | 0.88 | MAPT (0.70) | RECQLMAPTLMNAPLIN1PLIN5 | |
| SCHEMBL2954318 | 0.88 | MAPT (0.70) | RECQLMAPTLMNAPLIN1PLIN5 | |
| SCHEMBL2954324 | 0.88 | MAPT (0.70) | RECQLMAPTLMNAPLIN1PLIN5 | |
| SCHEMBL8534126 | 0.88 | SMN1; SMN2 (0.59) | RECQLMAPTLMNACYP1B1ALDH1A1 | |
| SCHEMBL8536033 | 0.88 | SMN1; SMN2 (0.59) | RECQLMAPTLMNACYP1B1ALDH1A1 | |
| SCHEMBL8534131 | 0.88 | SMN1; SMN2 (0.59) | RECQLMAPTLMNACYP1B1ALDH1A1 | |
| Chalcone SCHEMBL4635269 | 0.82 | CYP1B1 (0.81) | RECQLMAPTLMNAPLIN1PLIN5 | |
| SCHEMBL312429 | 0.81 | ALDH1A1 (0.68) | RECQLMAPTLMNAPLIN1PLIN5 | |
| SCHEMBL5585936 | 0.81 | ALDH1A1 (0.68) | RECQLMAPTLMNAPLIN1PLIN5 | |
| SCHEMBL312430 | 0.81 | ALDH1A1 (0.68) | RECQLMAPTLMNAPLIN1PLIN5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | claimed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | claimed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | claimed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | RECQL 4334/4885MAPT 1770/4885LMNA 2887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.